Numero AI and Royu Merge to Redefine How Finance Teams Operate

Numero AI has acquired Royu in an undisclosed cash-and-stock transaction to combine AI-first fintech capabilities for enterprise finance operations. The merger brings together Royu's engineering expertise with Numero's finance domain knowledge to expand agentic AI systems across accounting close, reconciliation, reporting, order-to-cash, and technical accounting workflows. Royu co-founders Viswajith and Sathya will join Numero's leadership as Chief Product Officer and Chief Technology Officer respectively.

05/21/2026, 10:30 AM • Benzinga

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased uniQure N.V. securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resulting in investor losses.

04/13/2026, 9:00 AM • GlobeNewswire

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorting comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

04/10/2026, 1:53 PM • GlobeNewswire

INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman

Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorted comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA agreement was revealed. Investors with losses during September 24 - October 31, 2025, have until April 13, 2026, to join the class action lawsuit.

04/08/2026, 4:57 PM • GlobeNewswire

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. faces a securities fraud class action lawsuit after the FDA rejected the company's data for its lead drug candidate AMT-130, causing a 49% stock price decline from $67.69 to $34.29 on November 3, 2025. Investors who purchased shares between September 24 and October 31, 2025 can file lead plaintiff applications by April 13, 2026.

04/07/2026, 9:47 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, NuScale Power Corporation, and uniQure N.V. The AMC lawsuit concerns alleged securities fraud related to APE (Preferred Equity Units) holders being excluded from a special dividend due to a technical loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

04/07/2026, 3:59 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE

Pomerantz Law Firm has filed class action lawsuits against uniQure N.V., AMC Entertainment Holdings, Inc., and NuScale Power Corporation on behalf of investors who suffered losses. The primary focus is on uniQure, which experienced a 49.34% stock price decline following FDA feedback that Phase I/II study data for its AMT-130 gene therapy may be inadequate for a Biologics License Application submission. Investors have until April 13, 2026, to request Lead Plaintiff status.

04/07/2026, 3:49 PM • GlobeNewswire

ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOM

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. Trip.com Group Limited faces allegations of understating regulatory risks from monopolistic business activities. The firm is seeking lead plaintiffs with a May 11, 2026 deadline for Trip.com investors who purchased securities between April 30, 2024 and January 13, 2026.

04/05/2026, 10:03 PM • GlobeNewswire

UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

Rosen Law Firm is notifying investors in uniQure N.V., Inovio Pharmaceuticals, and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. uniQure faces allegations of misrepresenting FDA approval status of its Pivotal Study and downplaying delays to its Biologics License Application timeline. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

04/05/2026, 9:32 PM • GlobeNewswire

INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm is notifying investors in Inovio Pharmaceuticals, uniQure N.V., and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. Inovio faces allegations of false statements regarding manufacturing deficiencies and overstated regulatory prospects for its INO-3107 product. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

04/05/2026, 9:27 PM • GlobeNewswire

QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Hagens Berman is investigating uniQure N.V. following FDA officials' public rebukes alleging the company misrepresented its interactions with the FDA and used an unapproved study design for its gene therapy candidate AMT-130. The FDA disputed uniQure's claims about sham surgery requirements and the use of external historical data as a control. A securities class action lawsuit covers investors who purchased shares between September 24 and October 31, 2025, with an April 13, 2026 deadline to become Lead Plaintiff.

04/04/2026, 11:19 AM • GlobeNewswire

UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

A securities class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting and failing to disclose issues with its Pivotal Study design and FDA approval status for its Huntington's Disease drug candidate. The lawsuit claims defendants downplayed the likelihood of delays to the Biologics License Application timeline. Investors who purchased shares between September 24, 2025 and October 31, 2025 have until April 13, 2026 to serve as lead plaintiff.

04/02/2026, 6:39 PM • GlobeNewswire

UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th

A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements regarding its Pivotal Study FDA approval and BLA timeline delays. Investors who purchased shares between September 24, 2025, and October 31, 2025, have until April 13, 2026, to apply as lead plaintiff.

04/02/2026, 5:51 PM • GlobeNewswire

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. faces a securities fraud class action lawsuit after the FDA rejected the company's data for its AMT-130 drug candidate, causing a 49% stock price decline from $67.69 to $34.29 on November 3, 2025. Investors who purchased shares between September 24 and October 31, 2025 can file lead plaintiff applications by April 13, 2026. The company allegedly failed to disclose material information about FDA approval likelihood during the class period.

03/31/2026, 10:50 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE

Pomerantz Law Firm has filed class action lawsuits against uniQure N.V. and other companies for alleged securities fraud. The lawsuit against uniQure stems from an FDA feedback on November 3, 2025, regarding its AMT-130 gene therapy for Huntington's disease, which caused the stock to plummet 49.34%. Investors have until April 13, 2026, to join as lead plaintiffs.

03/31/2026, 3:54 PM • GlobeNewswire